Skip to main content

Parkinson's Disease: A Healthcare Professional's Guide

Medically reviewed by Leigh Ann Anderson, PharmD. Last updated on Oct 27, 2022.

Parkinson's Disease: Etiology

Parkinson's disease (PD) is a progressive, chronic neurological condition, and affects more than 10 million people worldwide. In the US, approximately 60,000 Americans are diagnosed each year and roughly one million are living with PD.

Parkinson's disease occurs mainly in those over the age of 60, although older and much younger people may be diagnosed, as well. Four percent of people with PD are diagnosed before age 50, and men are 1.5 times more likely to have Parkinson's disease than women.

  • The cause of PD is still not fully known, but research is ongoing to identify biomarkers (such as work being done at the MJF Foundation).
  • It is known that neurons in the substantia nigra die and dopamine production declines, leading to progressive disease. The latest clues also point to involvement with Lewy Bodies and the protein alpha-synuclein found within Lewy bodies in the brains of patients with Parkinson's disease.
  • Most research suggests that Parkinson's disease is due to a complicated mix of genetics and one's environment; however, only about 15% of those with PD also have a first-degree relative with PD.

Typical Signs and Symptoms of PD

Resting tremor, bradykinesia, and rigidity are the cardinal movement symptoms of PD.

  • Tremor, often seen in the hands, arms, legs, jaw, lips and face, tends to occur at rest (when relaxed) instead of during purposeful movement.
  • Unilateral tremor in the hand may often be the first noticed symptom.
  • Bradykinesia is seen in most patients but may not be a presenting sign.
  • Rigidity may be present in the trunk and limbs.
  • Feet shuffling, gait freezing, quick walking pace, loss of manual dexterity, and micrographia (small handwriting) may appear.
  • Postural instability and lack of coordination, both added risk factors for falling, often occurs later in the course of the disease.

Diagnosis of PD

Parkinson's disease is almost always diagnosed with a clinical evaluation, not a neurodiagnostic test.

  • Bradykinesia, plus either tremor or rigidity, should be present for a diagnosis of idiopathic PD.
  • Symptoms that first occur on one side (unilateral) and a resting tremor are other diagnostic clues.
  • If a patient's symptoms improve after taking dopaminergic medication, such as levodopa / carbidopa or a dopamine agonist, this supports the diagnosis.

Differential Diagnosis in Parkinson's Disease

The differential diagnosis list for Parkinson's disease is long. An evaluation by a qualified neurologist is important in Parkinson's disease, as many other syndromes can mimic its symptoms.

Other conditions that may be mistaken for PD include:

Risk Factors with Parkinson's Disease

Proposed Risk Factors

  • Older Age
  • Family history
  • Industrial/toxin/occupational exposures (e.g., manganese)
  • Head Trauma (e.g., concussions)
  • Obesity
  • Certain genetic traits
  • Being male

Pharmacotherapy of Parkinson's Disease

Ironically, medications used to treat the motor symptoms of PD can lead to dyskinesias (movement disorders). Knowing when to initiate treatment, add or discontinue agents, and adjust dosing can help to modify adverse events.

Agents used in PD treatment include:

Carbidopa and Levodopa: The Standard for Decades

Carbidopa and levodopa (brands include: Sinemet, Rytary, and generic options) has been a mainstay of PD since the 1960's.

  • Levodopa and carbidopa provides exogenous dopamine levels to the CNS and is considered the most effective therapy for symptoms.
  • Carbidopa is included to prevent the peripheral conversion of levodopa to dopamine and to help lower levodopa side effects such as nausea, vomiting and tachycardia
  • Levodopa and carbidopa is most effective for the treatment of bradykinesia and rigidity, but less effective for tremor, freezing, and postural instability.

Treatments should be individualized and other early therapies, such as the MAO-B inhibitor rasagiline (Azilect) or dopamine agonists such as pramipexole (Mirapex) may be preferred for initial or combined therapy.

A prospective, placebo-controlled, randomized study published in the New England Journal of Medicine in 2019 looked at early versus delayed start of levodopa in 445 patients. Early Parkinson's patients in the Netherlands were randomly assigned to either start levodopa therapy right away, or wait 40 weeks and then start taking the drug.

  • Results demonstrated early use of levodopa did not lead to development of significantly different rates of involuntary movement, such as dyskinesias and "OFF" episodes.
  • Researchers state it can be used more confidentally, but judiciously, in early disease when symptoms first appear. However, levodopa doesn't appear to provide any protection against progression of Parkinson's in the brain or have a disease-modifying effect.

Carbidopa and Levodopa: ADRs

Movement disorders like dyskinesias with carbidopa and levodopa can still be an issue with this drug. The timing of initial treatment with a neurologist is important, and symptoms should be present before initiation.

A wide range of other side effects may occur:

  • nausea, vomiting
  • postural hypotension
  • hallucination
  • psychosis
  • low blood pressure
  • tachycardia
  • confusion
  • dry mouth
  • dizziness
  • headaches
  • hallucinations
  • behavioral disturbances
  • "wearing off" phenomenon

Levodopa and carbidopa can lose effectiveness completely over time or only at certain times during the day. "Wearing-off", also called "end-of-dose" is partly due to the short half-life of levodopa, which leads to swings in plasma levodopa levels. Older patients may experience hallucinations, and dyskinesias may be more common with levodopa doses over 300 mg per day. Transient GI side effects may be tempered by taking in divided doses with meals.

Carbidopa and Levodopa: Dose Form Options

Options for carbidopa and levodopa combination forms include:

  • immediate-release tablets (Sinemet), Dhivy (scored), and generics
  • orally-disintegrating tablets (generic); Parcopa brand discontinued
  • enteral suspension (Duopa); generic not yet available
  • controlled-release tablets (generics); Sinemet CR brand discontinued
  • Rytary capsules, extended-release

See the individual monographs for the most recent dosing specifics. Dosing is started at the low end to lessen acute GI effects. Give in divided daily doses with meals. Dose may be titrated every 3 to 4 days based on tolerance. Taper doses gradually when discontinuing to lessen withdrawal effects.

End-of-Dose Wearing Off

Stalevo (carbidopa / levodopa / entacapone tablets)

  • The addition of entacapone to carbidopa/levodopa (brand: Stalevo) has been shown to lead to a greater degree of improvement in some Parkinson's disease symptoms than use of carbidopa/levodopa alone. Entacapone is a catechol-O-methyltransferase (COMT) inhibitor that boosts the effectiveness of levodopa by allowing a greater CNS penetration.
  • Stalevo may be an option when patients experience end-of-dose "wearing-off" and when the patient's total daily doses of levodopa are 600 mg or less without experiencing dyskinesias.

Inbrija (levodopa dry powder inhalation)

  • In December 2018, the FDA cleared Acorda Therapeutics’ Inbrija (levodopa), an oral, dry powder inhalation for the treatment of "OFF" episodes in people with Parkinson’s disease already taking a carbidopa and levodopa regimen.
  • In Phase 3 studies, a significant improvement in motor function was seen at week 12 compared to a placebo. Onset of action was as quick as 10 minutes.
  • Common side effects include cough, upper respiratory tract infection, nausea, and discolored sputum.

Dopamine Agonists: Another Tool

Dopamine agonists such as pramipexole (Mirapex [brand discontinued], Mirapex ER), ropinirole (Requip, Requip XL [both brands discontinued]), and transdermal rotigotine (Neupro) stimulate the post-synaptic dopamine receptors directly. This class causes less frequent dyskinesias than carbidopa/levodopa and can improve tremor, bradykinesia and rigidity. Generics are available for all ropinirole and pramipexole dose forms but a generic for Neupro patch is not yet on the market.

  • Dopamine agonists may be used first-line, especially in younger patients, to delay levodopa therapy and dyskinesias, and in combination with carbidopa/levodopa or MAO-B inhibitors.
  • Dopamine agonists can provide good control of motor symptoms for several years before levodopa therapy is required. However, these drugs may not be as effective as carbidopa/levodopa for more advanced disease.
  • Dopamine agonists are ineffective in patients who do not respond to levodopa.

In May 2020, the FDA approved Kynmobi (apomorphine sublingual film), a novel dopamine agonist dosage form for the on-demand management of "OFF" episodes associated with Parkinson’s disease (PD). Kynmobi dissolves under the tongue in about 3 minutes.

  • Treatment with an antiemetic such as trimethobenzamide is started 3 days prior to prior to use of Kynmobi due to high incidence of nausea / vomiting.
  • Doses should be separated by at least 2 hours.
  • Do not administer more than 5 doses per day.
  • The maximum single dose of Kynmobi is 30 mg.

See more dosing detail here: Kynmobi dosing

Dopamine Agonists: ADRs

Dopamine agonists can result in numerous CNS dose-related side effects: nausea, orthostatic hypotension, hallucinations, confusion, edema, psychosis, sedation, sudden sleep attacks, and impulse control disorders such as gambling and sexual obsessions. Patients over 70 years may be especially prone to hallucinations with DAs.

  • Initial treatment with dopamine agonists in early disease may delay treatment and dyskinesias associated with carbidopa/levodopa.
  • However, dopamine agonist monotherapy many not be effective in advanced disease.
  • Taking doses after meals may help to relieve nausea, and patients should be monitored closely.
  • Dopamine agonists may be combined with MAOBIs in early disease to delay levodopa.

Dopamine Agonists: Formulations & Dosing

Available dopamine agonists for treatment of Parkinson's disease include:

Dopamine agonists may be initiated when the activities of daily living are severely impacted. It's important to initiate treatment at the low end of dosing and titrate up based on efficacy and tolerability. This class can be used to treat all motor symptoms in Parkinson's, and as either monotherapy or as adjunct therapy.

The manufacturers of brand name (Permax) and generic pergolide, also a dopamine agonist, voluntarily removed these drugs from the U.S. market in 2007 because of the risk of serious damage to patients’ heart valves (valvulopathy). Two studies were published in 2007 in the NEJM warning of this risk.

Dopamine Agonists: Impulse Control Disorders

Parkinson's disease patients taking dopamine agonists may exhibit unusual behaviors, like compulsive shopping, gambling, or hypersexuality. In fact, impulse control disorders are found in roughly 10 percent of patients taking dopamine agonists.

A study published in JAMA Internal Medicine looked at over 10 years of safety data for these drugs and researchers reported that pramipexole (Mirapex) and ropinirole (Requip) were most frequently associated with this disorder. The compulsive behaviors usually improve or disappear when the dose is reduced or the drug is discontinued.

Place in Therapy: MAO-B Inhibitors

Monoamine oxidase functions in the CNS to metabolize dopamine to norepinephrine and serotonin (5-HT). MAO-B inhibitors block the metabolism and increase the availability of dopamine. They include: selegiline (Zelapar), rasagiline (Azilect) and safinamide (Xadago). The Eldepryl brand of selegiline has been discontinued.

As monotherapy, MAO-B inhibitors only modestly reduce motor fluctuations and treat early, mild symptoms. They may be added to dopamine agonists or levodopa in more advanced disease and to help to reduce "OFF" time.

Rasagiline studies have established efficacy for both monotherapy and as an adjunct. However, selegiline studies are conflicting for adjunct treatment in later disease, although the use of selegiline monotherapy for mild symptoms has been shown to be effective.

In March 2017, a new MAO-B inhibitor Xadago (safinamide) was approved as an add-on treatment for patients with Parkinson’s disease who are currently taking levodopa/carbidopa and experiencing “OFF” episodes.

MAO-B Inhibitors: Dosing and Side Effects

In general, the side effect profile with MAO-B inhibitors is good. Commercially available MAO-B inhibitors include:

Selegiline is dosed once or twice a day with breakfast and lunch. It is used as an adjunct to levodopa-carbidopa in patients who exhibit deterioration. Selegiline ODT (Zelapar) is an orally-disintegrating selegiline tablet given once daily before breakfast without any liquid. It is used only as an adjunct to levodopa and carbidopa therapy.

Rasagiline (Azilect) is an oral tablet given once a day. May be used as monotherapy or as an adjunct therapy.

Safinamide (Xadago) is a tablet given once daily. It has not been shown to be effective as monotherapy for the treatment of Parkinson's disease, so it is used only in combination with levodopa and carbidopa.

Side effects with MAO-B inhibitors can include:

  • stimulation, confusion (selegiline)
  • arthralgia, dyspepsia, depression, flu-like syndrome, and constipation (rasagiline)
  • dyskinesia, fall, nausea, and insomnia (safinamide)
  • dizziness, headaches and worsening of levodopa side effects can also occur.

Any MAO-B inhibitor should be slowly discontinued to lessen withdrawal side effects.

COMT Inhibitors: Entacapone, Tolcapone, Opicapone

COMTIs on the market include:

COMTIs, or catechol-O-methyltransferase inhibitors, are a useful adjunct to help manage motor fluctuations that do not respond to levodopa dose adjustments and help manage end-of-dose "wearing off". Symptoms such as tremor, slowed movement and difficulty walking may occur during “OFF” episodes in-between regular levodopa doses.

COMTIs block the peripheral metabolism of levodopa to 3-O-methyldopa, lengthening the dopamine half-life and boosting brain dopamine availability.

COMTIs: Available Formulations

Entacapone (Comtan): Available as a 200 mg tablet. Comtan should always be administered in association with levodopa and carbidopa. Entacapone has no antiparkinsonian effect of its own. Review Comtan dosing here.

Carbidopa/levodopa/entacapone (Stalevo): Available in 6 strengths. Clinical experience with daily doses above 1,600 mg of entacapone is limited. The maximum recommended daily dose of Stalevo depends on the strength used. Stalevo dosing is available here.

Tolcapone (Tasmar): Available as 100 mg tablet. Only prescribe tolcapone for patients taking concomitant carbidopa levodopa therapy. Stop tolcapone therapy if no benefit after 3 weeks at the maximum dose due to risk of liver failure. See Boxed Warning and dosing here.

Opicapone (Ongentys): Available as 25 and 50 mg oral capsules. Adjust dose or avoid Ongentys with certain levels of hepatic impairment. Ongentys was approved in April 2020 as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease (PD) experiencing “OFF” episodes.

COMTIs: Adverse Effect Profile

COMTIs can lead to levodopa toxicity, including dyskinesias, hallucinations, and confusion, due to the fact that they boost levodopa availability in the CNS.

Patients should be warned that entacapone (Comtan), as well as the triple combo agent carbidopa/levodopa/entacapone (Stalevo) can cause the urine to turn orange.

There have only been very rare reports of liver toxicity with entacapone but post-marketing hepatitis has been reported. Entacapone should be administered with care to patients with liver impairment or biliary obstruction as biliary excretion appears to be the major route of excretion of this drug.

However, tolcapone (Tasmar) can lead to hepatoxicity, including acute hepatic failure.

  • AST/ALT should be followed at baseline, and then every 2 to 4 weeks for 6 months after initiation of treatment or any dose increase; then periodically as deemed clinical relevant by the provider. See Boxed Warning for additional tolcapone (Tasmar) information related to liver function monitoring.
  • Tolcapone should be discontinued if LFT levels exceed 2 times the upper limit of normal or if clinical signs and symptoms suggest the onset of hepatic impairment (persistent nausea, fatigue, lethargy, anorexia, jaundice, dark urine, pruritus, and right upper quadrant tenderness).
  • Tolcapone should only be used to control motor fluctuations in patients taking levodopa that can't be controlled with other medications.

Dyskinesias, hallucinations, and confusion are possible effects. Other common COMTI side effects include nausea/vomiting, diarrhea, orthostatic hypotension, and dizziness. Do not abruptly discontinue COMTIs, as it may lead to a syndrome of hyperpyrexia and confusion, a symptom complex resembling NMS.

Amantadine: An Antiviral for PD

Amantadine is an antiviral that has mild antiparkinsonian activity and may offer benefits to patients with bradykinesia, rigidity, or tremor. While its mechanism of action is unclear, amantadine appears to have positive dopaminergic effects.

Amantadine may provide short-term relief in mild, early-stage PD. It may also be given with carbidopa-levodopa in later stages to help control dyskinesias induced by carbidopa-levodopa. Immediate-release amantadine is available in tablets or capsules and an oral syrup.

Osmolex ER, an extended-release option for treatment of Parkinson’s Disease and drug-induced movement disorder, was FDA-approved in Feb. 2018. The once-daily tablet is a unique formulation of immediate-release and extended-release amantadine. The effectiveness of Osmolex ER is based upon bioavailability studies that compared Osmolex ER to immediate-release amantadine. However, Osmolex ER is not interchangeable with other amantadine immediate- or extended-release products.

Gocovri, an extended-release capsule, was approved in August 2017.

Amantadine: Dosing and Side Effects

Immediate-release amantadine is usually started at 100 mg/day and slowly titrated to an initial maintenance dose of 100 mg given 2 times daily. May give up to 400 mg / day in divided doses, if needed. Onset of action is normally within 48 hours.

Osmolex ER comes as extended-release tablets containing 129 mg, 193 mg, or 258 milligrams (mg) of amantadine. The initial dosage is 129 mg orally once daily in the morning. The dosage may be increased in weekly intervals to a maximum daily dose of 322 mg once daily in the morning.

View more detailed dosing here.

Confusion and hallucinations may be the most concerning and troublesome side effect for patients and caregivers; other common side effects of amantadine include nausea, headache, dizziness, lightheadedness and insomnia.

Less common side effects include livedo reticularis and peripheral edema.

Long-Acting Gocovri: Movement Disorders & "OFF" Episodes

Dyskinesias are involuntary movements that occur due to levodopa-based Parkinson's disease treatment and can impact activities of daily living. It can be common in patients and affects about 150,000 to 200,000 people with Parkinson's disease.

  • In August 2017, the FDA approved Gocovri (amantadine) extended-release capsules for treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, used with or without dopaminergic medications.
  • In Feb. 2021, Gocovri was also approved to be used in addition to levodopa / carbidopa in patients with Parkinson’s disease experiencing "OFF" episodes.

It's available as a 68.5 mg and 137 mg extended-release capsule. View Gocovri dosing in more detail.

The most commonly observed adverse reactions (>10% and greater than placebo) with Gocovri are hallucinations, dizziness, dry mouth, peripheral edema (fluid retention, swelling), constipation, falls and orthostatic hypotension (feedling dizzy when standing up due to low blood pressure).

Anticholinergics: Used for Tremor, But Problematic in the Elderly

Anticholinergic drugs, such as trihexyphenidyl or benztropine are effective for tremor in about half of the patients that do not respond to other treatments.

  • Anticholinergics can be used as monotherapy in patients younger than 60 to 65 whose main symptom is tremor.
  • However, due to troublesome neuropsychiatric side effects like memory impairment, confusion, hallucinations, and delirium, especially in the elderly over 65 to 70 years, anticholinergics should be avoided in this age group.
  • The Beers Guideline warns against use of anticholinergic drugs in the elderly when possible.
  • Other typical side effects of anticholinergics include dry mouth, blurred vision, urinary retention, and constipation.

Anticholinergics: Dosing Considerations

When used concomitantly with levodopa, the dose of both drugs may need to be reduced. Adjust doses based on side effects and symptom control

Nuplazid Approved for Parkinson’s Disease Psychosis

Treatment of psychosis in PD patients can be tricky as antipsychotic drugs often alter dopamine levels that can adversely affect PD symptoms.

  • In May 2016 FDA approved Acadia’s once-daily Nuplazid (pimavanserin) tablets, the first atypical antipsychotic to treat hallucinations and delusions associated with Parkinson’s disease psychosis (PDP).
  • Nuplazid exhibits inverse agonist and antagonist activity at serotonin 5-HT2A receptors and to a lesser extent at serotonin 5-HT2C receptors, but has no measurable activity at dopaminergic receptors.
  • In a six-week study, Nuplazid was shown to be superior to placebo in decreasing the frequency and / or severity of hallucinations and delusions without worsening the primary motor symptoms of Parkinson’s disease.

The recommended dose of Nuplazid is 34 mg taken orally once daily (without titration). Can be taken with or without food. Nuplazid comes as a 34-mg capsule and 10-mg oral tablet. If needed, the capsules may be opened and sprinkled over a tablespoon of applesauce, yogurt, pudding, or a liquid nutritional supplement.

Common side effects include: swelling (peripheral edema), nausea, and confusion. Nuplazid can also lead to QT interval prolongation. For patients taking strong CYP3A4 inhibitors, reduce the Nuplazid dose to 10 mg once daily. In those taking strong or moderate 3A4 inducers, avoid the use of Nuplazid.

Other Unique Agents

Although a Parkinson's disease cure does not yet exist, unique agents help to expand treatment options.

  • Duopa, approved in 2015, is a levodopa/carbidopa enteral suspension given via the small intestine using a surgically placed pump. Duopa, given over a 16 hour period, may help to lessen the “OFF" times as it can offer more stable plasma concentrations. See more detailed dosing here.

  • Northera (droxidopa) was approved in 2014 to help patients who have symptomatic neurogenic orthostatic hypotension (NOH) caused by primary autonomic failure. NOH can lead to a fall in blood pressure when a Parkinson disease patient stands, leading to dizziness or dangerous falls. Northera works by constricting (narrowing) the blood vessels and increasing blood pressure. It is also used for other conditions where neurogenic orthostatic hypotension is caused by primary autonomic failure

Nourianz Approved to Treat "OFF" Episodes in PD

During "OFF" episodes, medications are not working well and PD symptoms increase, which may include tremor and difficulty walking.

In 2019 the FDA approved Kyowa Kirin’s Nourianz (istradefylline), classified as an adenosine A2A receptor antagonist. Nourianz is used in conjunction with levodopa and carbidopa in adult patients with Parkinson’s disease experiencing “OFF” episodes. It is a once-a-day oral treatment. See dosing here.

  • Effectiveness of Nourianz was shown in four 12-week, placebo-controlled studies with over 1,100 participants already being treated with levodopa and carbidopa (Sinemet).
  • Nourianz led to a statistically significant decrease from baseline in daily “OFF” time compared to patients receiving a placebo in all 4 studies.
  • Common side effects include: involuntary muscle movement (dyskinesia), dizziness, constipation, nausea, hallucinations and trouble sleeping (insomnia).

Advances: What About Neuroprotection?

Neuroprotective therapies could help to protect further loss of neurons in the brain and slow disease progression, but no such drugs have been approved for Parkinson's disease -- yet.

There are multiple agents in research for preventing, slowing or halting the progression of Parkinson's disease. Many of these compounds are funded and researched by the Michael J Fox Foundation, and target proteins and pathways known to play a role in the disease.

Lifestyles Changes to Augment Drug Therapy

While drug therapy is the cornerstone of treatment for most PD patients, lifestyle adjustments can have a major impact, too.

Eating habits, such as a healthy diet high in fiber and plenty of water can help to prevent constipation. Exercise, possibly with a physical therapist, can help to keep muscles stronger and improve flexibility and balance. Learning to avoid falls and maintaining activities of daily living can boost confidence and lengthen independence. Work with an occupational therapist may be helpful.

  • Some patients and caregivers might find strength in joining the Support Group or Parkinson's disease news blog to voice concerns, share experiences, and keep up with the latest research. However, always follow the advice of your healthcare provider
  • Patients and families who may have an interest in joining a clinical trial should speak to their doctor. Find additional information on the Michael J. Fox Foundation's Fox Trial Finder.

Finished: Parkinson's Disease: A Healthcare Professional's Guide.

Don't Miss

Menopause Symptoms & Stages: What Woman Need to Know

Society tends to treat menopause as a disease; something to be avoided at all costs. But menopause can be positive. No more monthly mood swings, period accidents, or pregnancy worries. Self-confidence and self-knowledge...


  • FDA Approves Nourianz (istradefylline) as an Add-On Drug to Treat Off Episodes in Adults with Parkinson’s Disease. December 21, 2018. Accessed Oct. 27, 2022
  • FDA Approves Inbrija (levodopa inhalation powder) for Intermittent Treatment of OFF Episodes in People with Parkinson’s Disease. Accessed March 15, 2021.
  • Verschuur C, Suwijn S, Boel J, et al. Randomized Delayed-Start Trial of Levodopa in Parkinson’s Disease. N Engl J Med 2019; 380:315-324. Accessed Oct. 27, 2022 at DOI: 10.1056/NEJMoa1809983
  • FDA Approves Osmolex ER. Feb. 19, 2018. Accessed March 15, 2021.
  • FDA Approves Gocovri (amantadine) for the Treatment of Dyskinesia in Parkinson's Disease Patients. August 24, 2017. Accessed March 15, 2021.
  • Connolly B, Lang A. Pharmacologic Treatment of Parkinson's Disease: A Review. JAMA. 2014;311(16):1670-1683. February 14, 2019.
  • Caslake R, Macleod A, Ives N, et al. Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease. Cochrane Database Syst Rev. 2009 (4):CD006661
  • Gazewood JD, Richards DR, Clebak K. Parkinson Disease: An Update. Am Fam Physician. Feb 15;87(4):267-273. Accessed March 15, 2021.
  • Parkinson's disease causes. Michael J. Fox Foundation. Accessed Oct. 27, 2022 at
  • New Clues to Easing Side Effects From Parkinson's Disease. News Nov 18, 2015. Accessed March 15, 2021.
  • Suchowersky O, Reich S, Perlmutter J, Zesiewicz T, Gronseth G, Weiner WJ. Practice parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66(7):968–75.
  • Institute for Safe Medication Practices. ISMP Safety Alert. Delayed administration and contraindicated drugs place hospitalized Parkinson's disease patients at risk. Accessed Oct. 27, 2022 at
  • Akhtar de la Fuente, A. Parkinson's Disease: An Update in Drug Therapy. December 2015. ACPE No. 0798000014156L01.
  • Reichmann H, Emre M. Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone. Expert Rev Neurother. 2012 Feb;12(2):119-31. Accessed Oct. 27, 2022 at doi: 10.1586/ern.11.203
  • Medications in Trials. Michael J. Fox Foundation. Accessed Oct. 27, 2022 at
  • Grimes DA, Lang AE. Treatment of early Parkinson's disease. Can J Neurol Sci. 1999. Suppl 2:S39-44.
  • Schade R, Andersohn F, Suissa S, et al. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007; 356:29-38.
  • Zanettini R, Antonini A, Gatto G, et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007; 356:39-46

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.